drugset / Trial / NCT05842733

A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management

NCT05842733

Phase 2 Unknown 36 enrolled Sinew Pharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety, efficacy, and pharmacokinetics of oral SafeTynadol, Naldebain and Naldebain combine with SafeTynadol in the treatment of moderate to severe pain following knee replacement.

Timeline

Start
2023-07-25
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dinalbuphine sebacate Small molecule 37.5 mg Oral
Comparator SafeTynadol Unknown 650 mg Oral

Indications